[go: up one dir, main page]

ES2188140T3 - Utilizacion del factor de crecimiento de monocitos cd137 o un analogo funcional del mismo para producir un medicamento. - Google Patents

Utilizacion del factor de crecimiento de monocitos cd137 o un analogo funcional del mismo para producir un medicamento.

Info

Publication number
ES2188140T3
ES2188140T3 ES99910331T ES99910331T ES2188140T3 ES 2188140 T3 ES2188140 T3 ES 2188140T3 ES 99910331 T ES99910331 T ES 99910331T ES 99910331 T ES99910331 T ES 99910331T ES 2188140 T3 ES2188140 T3 ES 2188140T3
Authority
ES
Spain
Prior art keywords
produce
growth factor
monocit
same
medicinal product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99910331T
Other languages
English (en)
Inventor
Herbert Schwarz
Joachim Langstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merckle GmbH
Original Assignee
Merckle GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merckle GmbH filed Critical Merckle GmbH
Application granted granted Critical
Publication of ES2188140T3 publication Critical patent/ES2188140T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Utilización del factor de crecimiento de monocitos CD137 o un análogo funcional del mismo para producir un medicamento para estimular la proliferación de monocitos periféricos en un mamífero.
ES99910331T 1998-07-15 1999-03-05 Utilizacion del factor de crecimiento de monocitos cd137 o un analogo funcional del mismo para producir un medicamento. Expired - Lifetime ES2188140T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98103859 1998-07-15

Publications (1)

Publication Number Publication Date
ES2188140T3 true ES2188140T3 (es) 2003-06-16

Family

ID=8231533

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99910331T Expired - Lifetime ES2188140T3 (es) 1998-07-15 1999-03-05 Utilizacion del factor de crecimiento de monocitos cd137 o un analogo funcional del mismo para producir un medicamento.

Country Status (21)

Country Link
US (1) US6627200B1 (es)
EP (1) EP1059931B1 (es)
JP (1) JP2003521439A (es)
KR (1) KR20010041624A (es)
AT (1) ATE228371T1 (es)
AU (1) AU747063B2 (es)
BR (1) BR9908518A (es)
CA (1) CA2322684A1 (es)
CZ (1) CZ20003238A3 (es)
DE (1) DE59903541D1 (es)
DK (1) DK1059931T3 (es)
EE (1) EE200000510A (es)
ES (1) ES2188140T3 (es)
HU (1) HUP0102046A3 (es)
IS (1) IS1986B (es)
NO (1) NO20004393L (es)
NZ (1) NZ506695A (es)
PL (1) PL343427A1 (es)
PT (1) PT1059931E (es)
SI (1) SI1059931T1 (es)
WO (1) WO1999044629A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232896A1 (en) * 2001-10-04 2005-10-20 Herbert Schwarz Cd137 as a proliferation factor for hematopoietic stem cells
CA2496795C (en) 2002-08-28 2014-06-03 Paul B. Burton Compositions and methods for treating cardiovascular disease
EP1575672A2 (en) * 2002-12-16 2005-09-21 Herbert Schwarz Use of cd137 antagonists for the treatment of tumors
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2012043651A1 (ja) * 2010-09-30 2012-04-05 国立大学法人 熊本大学 ミエロイド系血液細胞の製造方法
EP2981334A4 (en) * 2013-04-03 2016-11-23 Univ California COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ACTIVITY

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03145499A (ja) * 1989-10-31 1991-06-20 Nippon Kosei Butsushitsu Gakujiyutsu Kiyougikai ヒト単球成長因子
DE4222980A1 (de) 1992-07-13 1994-01-20 Cassella Ag Verwendung von 2-(N-(2-Aminoethyl)amino)-essigsäure-derivaten
AU6827094A (en) * 1993-05-07 1994-12-12 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
ATE454449T1 (de) * 1993-09-16 2010-01-15 Univ Indiana Res & Tech Corp Menschlicher rezeptor h4-1bb
CA2108401A1 (en) * 1993-09-27 1995-03-28 Martin Lotz Receptor induced by lymphocyte activation in imflammatory response

Also Published As

Publication number Publication date
PT1059931E (pt) 2003-04-30
HUP0102046A3 (en) 2006-02-28
NZ506695A (en) 2005-01-28
DK1059931T3 (da) 2003-03-24
AU747063B2 (en) 2002-05-09
KR20010041624A (ko) 2001-05-25
NO20004393L (no) 2000-10-31
JP2003521439A (ja) 2003-07-15
WO1999044629A3 (de) 2000-01-06
SI1059931T1 (en) 2003-04-30
US6627200B1 (en) 2003-09-30
EP1059931A2 (de) 2000-12-20
EE200000510A (et) 2002-02-15
HUP0102046A2 (hu) 2001-10-28
IS1986B (is) 2005-02-15
PL343427A1 (en) 2001-08-13
ATE228371T1 (de) 2002-12-15
CZ20003238A3 (cs) 2001-10-17
BR9908518A (pt) 2000-11-21
NO20004393D0 (no) 2000-09-04
CA2322684A1 (en) 1999-09-10
EP1059931B1 (de) 2002-11-27
IS5613A (is) 2000-08-30
WO1999044629A2 (de) 1999-09-10
AU2932499A (en) 1999-09-20
DE59903541D1 (de) 2003-01-09

Similar Documents

Publication Publication Date Title
MXPA04003487A (es) Queratinocitos utilizables como sustancia biologicamente activa en el tratamiento de heridas.
BRPI9708566A (pt) Análogo de glp-2, análogo de peptìdeo glp-humano, peptìdeo, composição farmacêutica, uso de um análogo de glp-2, e, processo para identificar análogos intestinotróficos de glp-2.
ES2155817T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
ES2188586T3 (es) Utilizacion de inhibidores del complemento para la preparacion de un medicamento para la profilaxis y terapia de enfermedades inflamatorias intestinales y de la piel, asi como purpura.
ES2190653T3 (es) Productos de reaccion del acido hialuronico y de aminoacidos naturales y su utilizacion en composiciones cosmeticas y farmaceuticas.
SV1995000042A (es) Heteroaril-oxazolidinonas de 5 eslabones ref. le a 30523-sv
AR012614A1 (es) Una composicion farmaceutica para la fabricacion de un medicamento destinado para el tratamiento de una infeccion viral susceptible de tratamientocon interferon alfa, un metodo para la fabricacion de un medicamento, el uso de peg12000-ifn alfa para la fabricacion de un medicamento
BR0009964A (pt) Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial
ES2154253T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas.
DE69825740D1 (de) Duftstoffvorläufer
ES2151467T1 (es) Inhibicion de la actividad de la quinasa p38 por aril-ureas.
ES2172533T3 (es) Uso de nonapeptidos y decapeptidos para la preparacion de un medicamento para combatir el sida.
ES2196082T3 (es) Analagos del factor de crecimiento de queratinocitos.
GB9806632D0 (en) Peptide factor
ES2181165T3 (es) Uso de un peptido asociado a la latencia para la preparacion de un medicamento para aumentar la curacion de heridas.
DE69033970D1 (de) Huperzin a analoge verbindungen
ATE274916T1 (de) Verwendung von substanzen mit oxytocinwirkung zur herstellung eines arzneimittels zur behandlung affektiver schmerzsyndrome
ES2159403T3 (es) Poliuretanos termoplasticos que contienen principios activos.
ITMI992107A0 (it) Uso del baclofen nel trattamento dell'astinenza da etanolo
ES2057004T3 (es) N-alcoxialquilamidas de hidroxiacidos y composiciones a base de las mismas para el tratamiento de la piel.
ES2188140T3 (es) Utilizacion del factor de crecimiento de monocitos cd137 o un analogo funcional del mismo para producir un medicamento.
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
HUP0401593A2 (hu) A PTX3 hosszú pentraxin alkalmazása gyógyhatású készítmény előállítására autoimmun betegségek megelőzésére és kezelésére
ES2089286T3 (es) Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos.
ES2150415T3 (es) Peptidos antimicrobianos y resistencia a enfermedades de plantas basadas en ellos.